Onyvax Ltd. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 34
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: OE6F408311DEN
Leaflet:

Download PDF Leaflet

Onyvax Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Onyvax Ltd. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Onyvax Ltd. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Onyvax Ltd. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Onyvax Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Onyvax Ltd.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Onyvax Ltd.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Onyvax Ltd. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Onyvax Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Onyvax Ltd..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Onyvax Ltd. and identify potential opportunities in those areas.
Onyvax Ltd. Snapshot
Onyvax Ltd. Overview
Key Information
Key Facts
Onyvax Ltd. – Research and Development Overview
Key Therapeutic Areas
Onyvax Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Onyvax Ltd. – Pipeline Products Glance
Onyvax Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Onyvax Ltd. – Drug Profiles
Allogeneic Adenocarcinoma Cell-Based Vaccines + BCG Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
BCG vaccine + monoclonal antibody 105AD7 anti-idiotype vaccine + alum adjuvant
  Product Description
  Mechanism of Action
  R&D Progress
MOAB 105AD7 + Allogeneic Adenocarcinoma Cell-Based Vaccines + BCG Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine + Alum Adjuvant
  Product Description
  Mechanism of Action
  R&D Progress
Monoclonal Antibody 105AD7 Anti-Idiotype Vaccine + BCG Vaccine
  Product Description
  Mechanism of Action
  R&D Progress
Onyvax Ltd. – Pipeline Analysis
Onyvax Ltd. – Pipeline Products by Therapeutic Class
Onyvax Ltd. Pipeline Products By Target
Onyvax Ltd. – Pipeline Products by Molecule Type
Onyvax Ltd. - Dormant Projects
Onyvax Ltd. – Locations And Subsidiaries
Head Office
Recent Developments
Mar 27, 2006: CD55 Is Over Expressed On Prostate Cancer, Promotes Cancer Cell Survival And Contributes To Metastatic Potential, According To New Data
Mar 27, 2006: CD55 Is Over Expressed On Prostate Cancer, Promotes Cancer Cell Survival And Contributes To Metastatic Potential, According To New Data
Apr 19, 2005: Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results In Osteosarcoma Patients After Intensive Chemotherapy
Apr 19, 2005: Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results In Osteosarcoma Patients After Intensive Chemotherapy
Jan 15, 2004: Onyvax And The Mayo Clinic Annouces To Develop Cancer Vaccines For Ovarian Cancer
Financial Deals Landscape
Onyvax Ltd., Deals Summary, 2004 to 2010
Onyvax Ltd. Detailed Deal Summary
Acquisition
Oldcastle Materials acquires 50% equity stake in American Cement Company
Venture Financing
Onyvax Secures $14.88 Million In Series C Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 34

LIST OF TABLES

Onyvax Ltd. – Pipeline by Therapy Area and Indication, 2010
Onyvax Ltd. – Pipeline by Stage of Development, 2010
Onyvax Ltd. – Monotherapy Products in Pipeline, 2010
Onyvax Ltd. – Combination Treatment Modalities in Pipeline, 2010
Onyvax Ltd. - Phase II, 2010
Onyvax Ltd. - Pipeline By Therapeutic Class, 2010
Onyvax Ltd. - Pipeline By Target, 2010
Onyvax Ltd. – Pipeline By Molecule Type, 2010
Onyvax Ltd. - Dormant Developmental Projects, 2010
Onyvax Ltd., Deals Summary, 2004 to 2010
Oldcastle Materials acquires 50% equity stake in American Cement Company
Onyvax Secures $14.88 Million In Series C Financing 31

LIST OF FIGURES

Onyvax Ltd. – Pipeline by Therapy Area and Indication, 2010
Onyvax Ltd. – Pipeline by Stage of Development, 2010
Onyvax Ltd. – Monotherapy Products in Pipeline, 2010
Onyvax Ltd. – Combination Treatment Modalities in Pipeline, 2010
Onyvax Ltd. – Pipeline By Therapeutic Class, 2010
Onyvax Ltd. - Pipeline By Target, 2010
Onyvax Ltd. – Pipeline By Molecule Type, 2010 22
KAEL-GemVax - Product Pipeline Review - Q4 2010 US$ 450.00 Dec, 2010 · 26 pages
Biofrontera AG - Product Pipeline Review - Q4 2010 US$ 450.00 Nov, 2010 · 41 pages
Bio-Link - Product Pipeline Review - Q4 2010 US$ 450.00 Nov, 2010 · 31 pages
Egalet a s - Product Pipeline Review - Q4 2010 US$ 450.00 Nov, 2010 · 25 pages

Ask Your Question

Onyvax Ltd. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: